These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 16979435)

  • 41. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.
    Molina A; Krishnan A; Fung H; Flinn IW; Inwards D; Winter JN; Nademanee A
    Curr Stem Cell Res Ther; 2007 Sep; 2(3):239-48. PubMed ID: 18220907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
    J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Riley MB; Gordon LI
    Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):8-13. PubMed ID: 15160856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
    Kawashima H
    ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
    Wiseman GA; Witzig TE
    Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma.
    Borghaei H; Wallace SG; Schilder RJ
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S16-21. PubMed ID: 15498145
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
    Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
    J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
    Blum KA; Bartlett NL
    Expert Opin Biol Ther; 2004 Aug; 4(8):1323-31. PubMed ID: 15268665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].
    Setoain X; López-Guillermo A; Ruiz A; Pons F
    Rev Esp Med Nucl; 2006; 25(1):55-68; quiz 69-70.. PubMed ID: 16540015
    [No Abstract]   [Full Text] [Related]  

  • 50. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
    Morschhauser F; Dreyling M; Rohatiner A; Hagemeister F; Bischof Delaloye A
    Oncologist; 2009; 14 Suppl 2():17-29. PubMed ID: 19819921
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal antibodies conjugated with radioisotopes for the treatment of Non-Hodgkin's lymphoma.
    Bush S
    Semin Oncol Nurs; 2002 Feb; 18(1 Suppl 1):16-21. PubMed ID: 11878047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
    J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [New trends in non-Hodgkin's lymphoma therapy].
    Mazur G; Wróbel T; Jurczak W; Butrym A
    Postepy Hig Med Dosw (Online); 2006; 60():707-21. PubMed ID: 17245320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.
    Postema EJ; Oyen WJ; Boerman OC; Corstens FH
    J Nucl Med; 2003 May; 44(5):853. PubMed ID: 12732690
    [No Abstract]   [Full Text] [Related]  

  • 55. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
    Ansell SM; Schilder RJ; Pieslor PC; Gordon LI; Emmanouilides C; Vo K; Czuczman MS; Witzig TE; Theuer C; Molina A
    Clin Lymphoma; 2004 Dec; 5(3):202-4. PubMed ID: 15636698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Zimmer AM
    Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
    Friedberg JW; Fisher RI
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Indications for radioimmunotherapy for patients with non-Hodgkin's lymphoma].
    Frølund UC; Hansen PB
    Ugeskr Laeger; 2011 May; 173(20):1417-21. PubMed ID: 21586245
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
    Hagenbeek A; Lewington V
    Ann Oncol; 2005 May; 16(5):786-92. PubMed ID: 15802280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.
    Santos ES; Kharfan-Dabaja MA; Ayala E; Raez LE
    Leuk Lymphoma; 2006 Dec; 47(12):2453-76. PubMed ID: 17169792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.